vs
Essex Property Trust（ESS）与West Pharmaceutical Services（WST）财务数据对比。点击上方公司名可切换其他公司
West Pharmaceutical Services的季度营收约是Essex Property Trust的1.7倍（$805.0M vs $479.6M），Essex Property Trust净利率更高（17.9% vs 16.4%，领先1.5%），West Pharmaceutical Services同比增速更快（7.5% vs 5.5%），过去两年West Pharmaceutical Services的营收复合增速更高（7.6% vs 6.0%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
美国West Pharmaceutical Services是注射用药品包装及给药系统的设计和制造商，1923年成立，总部位于宾夕法尼亚州埃克斯顿。成立初期主营注射类药物包装用橡胶组件，曾为青霉素和胰岛素生产商提供符合无菌要求的配套产品。
ESS vs WST — 直观对比
营收规模更大
WST
是对方的1.7倍
$479.6M
营收增速更快
WST
高出2.0%
5.5%
净利率更高
ESS
高出1.5%
16.4%
两年增速更快
WST
近两年复合增速
6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $805.0M |
| 净利润 | $85.7M | $132.1M |
| 毛利率 | 70.0% | 37.8% |
| 营业利润率 | 31.7% | 19.5% |
| 净利率 | 17.9% | 16.4% |
| 营收同比 | 5.5% | 7.5% |
| 净利润同比 | -71.6% | 1.5% |
| 每股收益（稀释后） | $1.24 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSWST
| Q4 25 | $479.6M | $805.0M | ||
| Q3 25 | $473.3M | $804.6M | ||
| Q2 25 | $469.8M | $766.5M | ||
| Q1 25 | $464.6M | $698.0M | ||
| Q4 24 | $454.5M | $748.8M | ||
| Q3 24 | $450.7M | $746.9M | ||
| Q2 24 | $442.4M | $702.1M | ||
| Q1 24 | $426.9M | $695.4M |
净利润ESSWST
| Q4 25 | $85.7M | $132.1M | ||
| Q3 25 | $172.7M | $140.0M | ||
| Q2 25 | $231.5M | $131.8M | ||
| Q1 25 | $212.8M | $89.8M | ||
| Q4 24 | $301.7M | $130.1M | ||
| Q3 24 | $125.5M | $136.0M | ||
| Q2 24 | $99.0M | $111.3M | ||
| Q1 24 | $285.1M | $115.3M |
毛利率ESSWST
| Q4 25 | 70.0% | 37.8% | ||
| Q3 25 | 69.2% | 36.6% | ||
| Q2 25 | 70.7% | 35.7% | ||
| Q1 25 | 69.6% | 33.2% | ||
| Q4 24 | 70.0% | 36.5% | ||
| Q3 24 | 69.5% | 35.4% | ||
| Q2 24 | 70.8% | 32.8% | ||
| Q1 24 | 69.7% | 33.1% |
营业利润率ESSWST
| Q4 25 | 31.7% | 19.5% | ||
| Q3 25 | 44.5% | 20.8% | ||
| Q2 25 | 59.5% | 20.1% | ||
| Q1 25 | 55.3% | 15.3% | ||
| Q4 24 | 67.0% | 21.3% | ||
| Q3 24 | 28.6% | 21.6% | ||
| Q2 24 | 31.1% | 18.0% | ||
| Q1 24 | 31.0% | 17.7% |
净利率ESSWST
| Q4 25 | 17.9% | 16.4% | ||
| Q3 25 | 36.5% | 17.4% | ||
| Q2 25 | 49.3% | 17.2% | ||
| Q1 25 | 45.8% | 12.9% | ||
| Q4 24 | 66.4% | 17.4% | ||
| Q3 24 | 27.8% | 18.2% | ||
| Q2 24 | 22.4% | 15.9% | ||
| Q1 24 | 66.8% | 16.6% |
每股收益（稀释后）ESSWST
| Q4 25 | $1.24 | $1.82 | ||
| Q3 25 | $2.56 | $1.92 | ||
| Q2 25 | $3.44 | $1.82 | ||
| Q1 25 | $3.16 | $1.23 | ||
| Q4 24 | $4.00 | $1.78 | ||
| Q3 24 | $1.84 | $1.85 | ||
| Q2 24 | $1.45 | $1.51 | ||
| Q1 24 | $4.25 | $1.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | $791.3M |
| 总债务越低越好 | — | $202.8M |
| 股东权益账面价值 | $5.5B | $3.2B |
| 总资产 | $13.2B | $4.3B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ESSWST
| Q4 25 | $76.2M | $791.3M | ||
| Q3 25 | $66.0M | $628.5M | ||
| Q2 25 | $58.7M | $509.7M | ||
| Q1 25 | $98.7M | $404.2M | ||
| Q4 24 | $66.8M | $484.6M | ||
| Q3 24 | $71.3M | $490.9M | ||
| Q2 24 | $55.2M | $446.2M | ||
| Q1 24 | $499.0M | $601.8M |
总债务ESSWST
| Q4 25 | — | $202.8M | ||
| Q3 25 | $6.4B | $202.7M | ||
| Q2 25 | $6.4B | $202.6M | ||
| Q1 25 | $6.8B | $202.6M | ||
| Q4 24 | — | $202.6M | ||
| Q3 24 | $6.4B | $202.6M | ||
| Q2 24 | $6.2B | $205.8M | ||
| Q1 24 | $6.6B | $206.2M |
股东权益ESSWST
| Q4 25 | $5.5B | $3.2B | ||
| Q3 25 | $5.6B | $3.1B | ||
| Q2 25 | $5.6B | $2.9B | ||
| Q1 25 | $5.6B | $2.7B | ||
| Q4 24 | $5.5B | $2.7B | ||
| Q3 24 | $5.4B | $2.8B | ||
| Q2 24 | $5.5B | $2.6B | ||
| Q1 24 | $5.5B | $2.7B |
总资产ESSWST
| Q4 25 | $13.2B | $4.3B | ||
| Q3 25 | $13.2B | $4.1B | ||
| Q2 25 | $13.2B | $4.0B | ||
| Q1 25 | $13.2B | $3.6B | ||
| Q4 24 | $12.9B | $3.6B | ||
| Q3 24 | $12.6B | $3.7B | ||
| Q2 24 | $12.5B | $3.5B | ||
| Q1 24 | $12.9B | $3.6B |
负债/权益比ESSWST
| Q4 25 | — | 0.06× | ||
| Q3 25 | 1.15× | 0.07× | ||
| Q2 25 | 1.14× | 0.07× | ||
| Q1 25 | 1.22× | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | 1.18× | 0.07× | ||
| Q2 24 | 1.13× | 0.08× | ||
| Q1 24 | 1.19× | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $251.1M |
| 自由现金流经营现金流 - 资本支出 | — | $175.0M |
| 自由现金流率自由现金流/营收 | — | 21.7% |
| 资本支出强度资本支出/营收 | — | 9.5% |
| 现金转化率经营现金流/净利润 | 12.53× | 1.90× |
| 过去12个月自由现金流最近4个季度 | — | $468.9M |
8季度趋势，按日历期对齐
经营现金流ESSWST
| Q4 25 | $1.1B | $251.1M | ||
| Q3 25 | $342.6M | $197.2M | ||
| Q2 25 | $216.1M | $177.1M | ||
| Q1 25 | $281.5M | $129.4M | ||
| Q4 24 | $1.1B | $190.1M | ||
| Q3 24 | $316.2M | $180.1M | ||
| Q2 24 | $218.9M | $165.0M | ||
| Q1 24 | $314.9M | $118.2M |
自由现金流ESSWST
| Q4 25 | — | $175.0M | ||
| Q3 25 | — | $133.9M | ||
| Q2 25 | — | $101.9M | ||
| Q1 25 | — | $58.1M | ||
| Q4 24 | — | $85.2M | ||
| Q3 24 | — | $98.8M | ||
| Q2 24 | — | $64.8M | ||
| Q1 24 | — | $27.6M |
自由现金流率ESSWST
| Q4 25 | — | 21.7% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | — | 4.0% |
资本支出强度ESSWST
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 9.8% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | 14.0% | ||
| Q3 24 | — | 10.9% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 13.0% |
现金转化率ESSWST
| Q4 25 | 12.53× | 1.90× | ||
| Q3 25 | 1.98× | 1.41× | ||
| Q2 25 | 0.93× | 1.34× | ||
| Q1 25 | 1.32× | 1.44× | ||
| Q4 24 | 3.54× | 1.46× | ||
| Q3 24 | 2.52× | 1.32× | ||
| Q2 24 | 2.21× | 1.48× | ||
| Q1 24 | 1.10× | 1.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
